The Cardiovascular Effects of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes: A randomizes dpoble-blind placebo-controlled crossover study (the AddHope2 study)

Preman  Kumarathurai

The Cardiovascular Effects of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes: A randomizes dpoble-blind placebo-controlled crossover study (the AddHope2 study)

Preman Kumarathurai

Hjerteafd. Y

Originalsprog	Engelsk

Status	Udgivet - 2016

Citationsformater

@phdthesis{add8a6c7c3ad4a5eb7da4acf3ac854f9,

title = "The Cardiovascular Effects of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes: A randomizes dpoble-blind placebo-controlled crossover study (the AddHope2 study)",

author = "Preman Kumarathurai",

year = "2016",

language = "English",

}

TY - BOOK

T1 - The Cardiovascular Effects of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes

T2 - A randomizes dpoble-blind placebo-controlled crossover study (the AddHope2 study)

AU - Kumarathurai, Preman

PY - 2016

Y1 - 2016

M3 - Ph.D. thesis

BT - The Cardiovascular Effects of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide in Patients with Coronary Artery Disease and Newly Diagnosed Type 2 Diabetes

ER -